EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy (LYMRIN-Trial): Project study by the Japan Pancreas Society and JON 2302-P

Nana Kimura, Yoshihiro Shirai iD, Ayaka Itoh, Katsuhisa Hirano, Kazuto Shibuya iD, Kenta Murotani iD, Makoto Ueno, Sohei Satoi, Hiroaki Nagano, Junji Furuse, Yoshifumi Takeyama, Tsutomu Fujii iD und 1 weitere

PLOS One · 2025

DOI: 10.1371/journal.pone.0325667 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift PLOS One, 2025. Verfasst von Nana Kimura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Lymph Node Excision, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Committee for the Promotion of Clicinal Research of the Japanc Pancreas Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Clear evidence regarding the optimal extent of lymph node dissection during pancreatectomy for pancreatic ductal adenocarcinoma (PDAC) is lacking. The index of estimated benefit of lymph node dissection is useful for evaluating the effectiveness of dissection at each lymph node station, but a prospective study is needed for accurate assessment. The aim of the LYMRIN trial is to determine the optimal station of lymph node dissection in pancreatectomy after neoadjuvant chemotherapy using gemcitabine and S-1 (GS) by evaluating the rate of lymph node metastasis and the index of estimated benefit of each type of lymph node dissection.

Methods

This multicenter prospective interventional trial in Japan that will include a total of 545 PDAC patients (head: 200 patients, body: 165 patients, and tail 180 patients) from 42 leading institutions and hospitals in Japan. Patients diagnosed with resectable PDAC after neoadjuvant GS therapy will be considered eligible for inclusion. Eligible patients will undergo pancreatoduodenectomy or distal pancreatectomy with regional lymph node dissection. The primary endpoint is the percentage of metastases in each lymph node station.

Discussion

The results of this study will clarify the optimal extent of lymph node dissection, allowing for a more conservative surgical approach, thereby avoiding unnecessary invasive procedures for patients.

Trial registration

University Hospital Medical Information Network Clinical Trials Registry, UMIN 000051879. Registered 1 October 2023, https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000059119

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsLymph Node ExcisionCarcinoma, Pancreatic DuctalHumansNeoadjuvant TherapyProspective StudiesJapanPancreatectomyGemcitabineDeoxycytidineOxonic AcidLymphatic MetastasisTegafurFemaleMaleDrug CombinationsLymph NodesMiddle AgedAged

Substanzen

GemcitabineS 1 (combination)DeoxycytidineOxonic AcidTegafurDrug Combinations

Autor:innen und Institutionen

  • Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.
  • Biostatistics Center, Kurume University Graduate School of Medicine, Kurume, Fukuoka, Japan.
  • School of Medical Technology, Kurume University, Kurume-shi, Fukuoka, Japan.
  • Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
  • Department of Surgery, Kansai Medical University, Osaka, Japan.
  • Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.

ORCID-Profile: Yoshihiro Shirai, Kazuto Shibuya, Kenta Murotani, Tsutomu Fujii

Förderung

  • Committee for the Promotion of Clicinal Research of the Japanc Pancreas Society

Zitieren

APA

Kimura, N., Shirai, Y., Itoh, A., Hirano, K., Shibuya, K., Murotani, K., Ueno, M., Satoi, S., Nagano, H., Furuse, J., Takeyama, Y., Fujii, T., & LYMRIN-Trial collaborators (2025). A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy (LYMRIN-Trial): Project study by the Japan Pancreas Society and JON 2302-P. PLOS One. https://doi.org/10.1371/journal.pone.0325667

Vancouver

Kimura N, Shirai Y, Itoh A, Hirano K, Shibuya K, Murotani K, et al. A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy (LYMRIN-Trial): Project study by the Japan Pancreas Society and JON 2302-P. PLOS One. 2025. doi:10.1371/journal.pone.0325667

BibTeX
@article{Kimura2025,
  author = {Kimura, Nana and Shirai, Yoshihiro and Itoh, Ayaka and Hirano, Katsuhisa and Shibuya, Kazuto and Murotani, Kenta and Ueno, Makoto and Satoi, Sohei and Nagano, Hiroaki and Furuse, Junji and Takeyama, Yoshifumi and Fujii, Tsutomu and LYMRIN-Trial collaborators, LYMRIN-Trial collaborators},
  title = {A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy (LYMRIN-Trial): Project study by the Japan Pancreas Society and JON 2302-P},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0325667}
}
Kostenlos starten →